# Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-for-platinum-and-cetuximab-refractory-head-and-neck-cancer-results/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Joshua Bauml,Tanguy Y. Seiwert,David G. Pfister,Francis P. Worden,Stephen V. Liu,Jill Gilbert,Nabil F. Saba,Jared Weiss,Lori J. Wirth,Ammar Sukari,Hyunseok Kang,Michael K. Gibson,Erminia Massarelli,Steven Powell,Amy Meister,Xinxin Shu,Jonathan D. Cheng,Robert I. Haddad |
| Citations | 657 |
| DOI | 10.1200/jco.2016.70.1524 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2602907503 |
| PMID | 28328302 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Stephen V. Liu](https://scholariq.org/researchers/stephen-v-liu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.